These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 32495988)

  • 1. No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes.
    Svane MS; Johannesen HH; Martinussen C; Bojsen-Møller KN; Hansen ML; Hansen AE; Deacon CF; Hartmann B; Keller SH; Klausen TL; Loft A; Kjaer A; Madsbad S; Löfgren J; Holst JJ; Wewer Albrechtsen NJ
    Diabetes Obes Metab; 2020 Oct; 22(10):1837-1846. PubMed ID: 32495988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.
    Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Pieters-van den Bos IC; Vendrik KE; Hoekstra T; Bruno MJ; Diamant M; van Raalte DH; Cahen DL
    Diabetes Care; 2017 Mar; 40(3):301-308. PubMed ID: 27998910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight.
    Svane MS; Johannesen HH; Hansen AE; Martinussen C; Bojsen-Møller KN; Hansen ML; Deacon CF; Keller SH; Klausen TL; Loft A; Kjaer A; Löfgren J; Madsbad S; Holst JJ; Wewer Albrechtsen NJ
    Int J Obes (Lond); 2022 Nov; 46(11):2058-2062. PubMed ID: 35982119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
    Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial.
    Yabe D; Eto T; Shiramoto M; Irie S; Murotani K; Seino Y; Kuwata H; Kurose T; Seino S; Ahrén B; Seino Y
    Diabetes Obes Metab; 2017 Mar; 19(3):442-447. PubMed ID: 27800649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
    Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Pouwels PJ; Pieters-van den Bos IC; Hoekstra T; Diamant M; van Raalte DH; Cahen DL
    Diabetologia; 2016 Dec; 59(12):2588-2593. PubMed ID: 27627981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
    Nguyen H; Dufour R; Caldwell-Tarr A
    Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway.
    Zhao H; Wang L; Wei R; Xiu D; Tao M; Ke J; Liu Y; Yang J; Hong T
    Diabetes Obes Metab; 2014 Sep; 16(9):850-60. PubMed ID: 24641303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes.
    Savchenko LG; Digtiar NI; Selikhova LG; Kaidasheva EI; Shlykova OA; Vesnina LE; Kaidashev IP
    Rom J Intern Med; 2019 Sep; 57(3):233-240. PubMed ID: 30901315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
    Lambadiari V; Pavlidis G; Kousathana F; Varoudi M; Vlastos D; Maratou E; Georgiou D; Andreadou I; Parissis J; Triantafyllidi H; Lekakis J; Iliodromitis E; Dimitriadis G; Ikonomidis I
    Cardiovasc Diabetol; 2018 Jan; 17(1):8. PubMed ID: 29310645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
    Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
    Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity.
    Lin CH; Shao L; Zhang YM; Tu YJ; Zhang Y; Tomlinson B; Chan P; Liu Z
    Expert Opin Pharmacother; 2020 Feb; 21(3):275-285. PubMed ID: 31790314
    [No Abstract]   [Full Text] [Related]  

  • 14. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
    Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS
    Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes.
    Ten Kulve JS; Veltman DJ; van Bloemendaal L; Barkhof F; Drent ML; Diamant M; IJzerman RG
    Diabetes Care; 2016 Feb; 39(2):214-21. PubMed ID: 26283736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effects of liraglutide are possibly influenced by hypertriglyceridemia and remaining pancreatic β-cell function in subjects with type 2 diabetes mellitus.
    Tanabe A; Kaneto H; Kamei S; Hirukawa H; Shimoda M; Kimura T; Obata A; Okauchi S; Tatsumi F; Kohara K; Mune T; Kaku K
    J Diabetes Complications; 2016 Aug; 30(6):1201-3. PubMed ID: 27220544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure-response analyses of liraglutide 3.0 mg for weight management.
    Wilding JP; Overgaard RV; Jacobsen LV; Jensen CB; le Roux CW
    Diabetes Obes Metab; 2016 May; 18(5):491-9. PubMed ID: 26833744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction.
    Pastel E; McCulloch LJ; Ward R; Joshi S; Gooding KM; Shore AC; Kos K
    Clin Sci (Lond); 2017 Mar; 131(5):343-353. PubMed ID: 28049736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
    Halawi H; Khemani D; Eckert D; O'Neill J; Kadouh H; Grothe K; Clark MM; Burton DD; Vella A; Acosta A; Zinsmeister AR; Camilleri M
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):890-899. PubMed ID: 28958851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment.
    von Scholten BJ; Lajer M; Goetze JP; Persson F; Rossing P
    Diabet Med; 2015 Mar; 32(3):343-52. PubMed ID: 25251901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.